The high-risk PNPLA3 GG variant LAMPS demonstrated increased steatosis, pro-inflammatory cytokine secretion, stellate cell activation, and secretion of the pro-fibrotic marker COL1A1 (Table 2), consistent with the clinical characterization of this polymorphism. Here, PNPLA3 is linked to steatosis.